Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1.
Bourafai-Aziez A, Benabderrahmane M, Paysant H, Weiswald LB, Poulain L, Carlier L, Ravault D, Jouanne M, Coadou G, Oulyadi H, Voisin-Chiret AS, Sopková-de Oliveira Santos J, Sebban M. Bourafai-Aziez A, et al. Among authors: paysant h. Drug Des Devel Ther. 2021 Dec 15;15:5035-5059. doi: 10.2147/DDDT.S323077. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34949914 Free PMC article.
Binding mode of Pyridoclax to myeloid cell leukemia-1 (Mcl-1) revealed by nuclear magnetic resonance spectroscopy, docking and molecular dynamics approaches.
Bourafai-Aziez A, Sebban M, Benabderrahmane M, Marekha B, Denis C, Paysant H, Weiswald LB, Carlier L, Bureau R, Coadou G, Ravault D, Voisin-Chiret AS, Sopková-de Oliveira Santos J, Oulyadi H. Bourafai-Aziez A, et al. Among authors: paysant h. J Biomol Struct Dyn. 2020 Sep;38(14):4162-4178. doi: 10.1080/07391102.2019.1680434. Epub 2019 Oct 29. J Biomol Struct Dyn. 2020. PMID: 31612791
Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids.
Vernon M, Lambert B, Meryet-Figuière M, Brotin E, Weiswald LB, Paysant H, Vigneron N, Wambecke A, Abeilard E, Giffard F, Louis MH, Blanc-Fournier C, Gauduchon P, Poulain L, Denoyelle C. Vernon M, et al. Among authors: paysant h. Mol Cancer Ther. 2020 Jul;19(7):1506-1519. doi: 10.1158/1535-7163.MCT-19-0510. Epub 2020 May 5. Mol Cancer Ther. 2020. PMID: 32371581
Pyridoclax-loaded nanoemulsion for enhanced anticancer effect on ovarian cancer.
Groo AC, Hedir S, Since M, Brotin E, Weiswald LB, Paysant H, Nee G, Coolzaet M, Goux D, Delépée R, Freret T, Poulain L, Voisin-Chiret AS, Malzert-Fréon A. Groo AC, et al. Among authors: paysant h. Int J Pharm. 2020 Sep 25;587:119655. doi: 10.1016/j.ijpharm.2020.119655. Epub 2020 Jul 23. Int J Pharm. 2020. PMID: 32712252
Structural revision of the Mcl-1 inhibitor MIM1: synthesis and biological studies on ovarian cancer cells with evaluation of designed analogues.
Paysant H, Hedir S, Justaud F, Weiswald LB, El Dine AN, Soulieman A, Hachem A, Elie N, Brotin E, Denoyelle C, Bignon J, Roussi F, Jouanne M, Tasseau O, Roisnel T, Voisin-Chiret AS, Grée R, Levoin N, Poulain L. Paysant H, et al. Org Biomol Chem. 2021 Oct 27;19(41):8968-8987. doi: 10.1039/d1ob01521d. Org Biomol Chem. 2021. PMID: 34596646 Free article.
Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.
Thorel L, Morice PM, Paysant H, Florent R, Babin G, Thomine C, Perréard M, Abeilard E, Giffard F, Brotin E, Denoyelle C, Villenet C, Sebda S, Briand M, Joly F, Dolivet E, Goux D, Blanc-Fournier C, Jeanne C, Villedieu M, Meryet-Figuiere M, Figeac M, Poulain L, Weiswald LB. Thorel L, et al. Among authors: paysant h. J Exp Clin Cancer Res. 2023 Oct 7;42(1):260. doi: 10.1186/s13046-023-02809-8. J Exp Clin Cancer Res. 2023. PMID: 37803448 Free PMC article.